CRISPR Therapeutics AG

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

CRISPR Therapeutics will present Phase 1b data for CTX310, its CRISPR/Cas9 in vivo gene editing therapy targeting ANGPTL3, in a late-breaking oral presentation at the AHA Scientific Sessions on November 9, 2026. The data covers patients with severe hypertriglyceridemia and will be embargoed until presentation time. CTX310 is one of three cardiovascular in vivo liver editing programs, alongside CTX340 for refractory hypertension and CTX321 for elevated Lp(a).

•24d ago

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics presented Phase 1a data for CTX310 demonstrating deep and durable reductions in ANGPTL3, triglycerides, and LDL sustained through one year of follow-up. At the highest dose, mean reductions were 79% for ANGPTL3, 48% for triglycerides, and 53% for LDL, with the data simultaneously published in the New England Journal of Medicine. The therapy was well tolerated with no treatment-related serious adverse events and no new safety signals during the extended follow-up period across the 15 participants. CRISPR is currently advancing CTX310 in Phase 1b trials and expects to provide an update on the severe hypertriglyceridemia cohort in the second half of 2026.

•2mo ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRISPR Therapeutics reported Q2 2026 total revenue of $10.2 million, driven by CASGEVY product revenue of $76 million, which grew 151% year-over-year. The FDA approved CASGEVY for children as young as 2 years old with SCD or TDT, significantly expanding the addressable patient population by approximately 5,500 individuals. Pipeline execution continued with the initiation of Phase 1 trials for CTX340 in refractory hypertension and CTX460 in alpha-1 antitrypsin deficiency. The company also provided updates on its CTX310, CTX611, and zugo-cel programs across cardiovascular and autoimmune indications. Financially, the net loss narrowed to $91.2 million from $208.5 million in the prior-year quarter, bolstered by a cash position of $2.36 billion. The balance sheet strength reflects recent convertible note proceeds and lower operating expenses.

•2mo ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

CRISPR Therapeutics reported Q1 2026 financial results featuring a strengthened balance sheet with $2.44 billion in cash, driven by $585.4 million in convertible note proceeds. Commercial momentum continued with CASGEVY generating $43 million in product revenue, as over 500 patients globally have initiated treatment. Pipeline advancement included FDA IND clearance for zugo-cel in autoimmune neurologic diseases and the progression of multiple in vivo liver programs. The company expects to initiate clinical trials for CTX340 (hypertension) in the first half of 2026 and CTX460 (AATD) by mid-2026. Operating discipline was evident as R&D expenses decreased to $68.6 million, contributing to a net loss of $122.9 million, an improvement from the prior year. Management emphasized that the strengthened financial position and upcoming milestones set the stage for a defining 2026.

•5mo ago